
Study Period | 2019 - 2030 |
Base Year For Estimation | 2024 |
Market Size (2025) | USD 46.36 Billion |
Market Size (2030) | USD 65.20 Billion |
CAGR (2025 - 2030) | 7.06 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Major Players![]() *Disclaimer: Major Players sorted in no particular order |
Peptide Therapeutics Market Analysis
The Peptide Therapeutics Market size is estimated at USD 46.36 billion in 2025, and is expected to reach USD 65.20 billion by 2030, at a CAGR of 7.06% during the forecast period (2025-2030).
The major factors driving the peptide therapeutics market growth are the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics. Peptides offer distinct advantages due to their specificity and ability to target multiple biological pathways. The rising prevalence of chronic diseases significantly drives the demand for peptide therapeutic products. For example, the 2024 updated data of the American Cancer Society projects an increase in new cancer cases from 1.9 million in 2023 to 2.0 million in 2024. In 2023, the most frequently diagnosed cancers were breast, lung, and hematological malignancies. This anticipated surge in cancer cases is poised to boost the adoption of peptide therapeutics, known for their efficacy in cancer treatment.
Additionally, supportive government legislations to promote the development of therapeutic peptides is further anticipated to offer new business avenues for market uptake. For instance, in April 2023, researchers at the Georgia Institute of Technology received a USD 700,000 grant from the National Science Foundation (NSF) to strengthen the discovery of therapeutic peptides for multiple sclerosis. Such grants are likely to support the discovery of novel peptide drugs, and such instances are anticipated to fuel market growth over the study period.
Furthermore, there is a growing opportunity to combine peptide-based therapies with other treatment modalities, such as immunotherapy or biologics, to improve outcomes, especially in oncology. However, peptides are highly susceptible to enzymatic degradation and can be unstable in biological environments, which limits their therapeutic potential. Overcoming these stability issues remains a significant challenge. In addition, peptide therapeutics industry analysis shows that intellectual property concerns and the complexity of obtaining patents for peptide drugs may restrict the market potential for smaller companies and new drug developers.
Peptide Therapeutics Market Insights and Trends
Branded Segment is Expected to Have Major Share in the Market Over the Forecast Period
By marketing type, the branded segment is estimated to have a market size of USD 36.82 billion in 2024, which is expected to reach USD 58.06 billion by 2029 with a CAGR of 10.47% during this period.
Branded peptides are peptide-based drugs developed, manufactured, and marketed by specific pharmaceutical companies under a proprietary brand name. These branded products often hold patents and are distinguished by their unique formulations, delivery systems, or applications. The increasing development of novel drugs by key players and favorable government regulations are expected to propel the growth of the branded segment over the forecast period. Also, the growing burden of chronic diseases such as cancer, cardiovascular disease, diabetes, osteoporosis, and mental health problems is increasing the demand for branded peptide therapeutics for managing these conditions.
Global peptide therapeutics market analysis show that many peptide drugs are being developed for rare diseases, and the government offers incentives such as orphan drug status to encourage innovation in this area. Orphan drug designation provides extended market exclusivity and reduces fees, which motivates manufacturing companies to invest in peptide drug development, further bolstering segment growth. For instance, in October 2023, UCB’s synthetic macrocyclic peptide, Zulicopan, received orphan drug status. It works by inhibiting the terminal complement cascade activation, employing a dual mechanism to prevent the formation of the membrane attack complex (MAC), and safeguarding the neuromuscular junction.
Furthermore, the rising investment by market leaders and key players to expand their peptide technology platform and peptide manufacturing facilities in the United States is expected to increase the production of peptide therapeutics for treating various diseases. This, in turn, is anticipated to spur segment growth over the forecast period. For instance, in July 2024, CordenPharma invested about EUR 900 million (USD 992.47 million) over the next three years to grow its peptide technology platform in the United States. The United States expansion involves bringing additional peptide capacity to the CordenPharma Colorado site with the planned construction of a new large-scale peptide manufacturing facility and a further increase in manufacturing sites in the existing facility, resulting from multiple long-term manufacturing contracts totaling about EUR 3 billion (USD 3.31 billion), with potential upsides.
Therefore, owing to the novel drug designation provided by the government and rising investment in developing branded peptides by key players, the branded segment of peptide therapeutics market is expected to grow over the forecast period.

The Parenteral Segment is Expected to Have a Major Share of the Market Over the Forecast Period
By route of administration, the parenteral segment is estimated to have a major peptide therapeutics market share with the segment’s estimated market size of USD 38.0 billion in 2024 which is expected to reach USD 60.28 billion by 2029 with a CAGR of 9.66% over the forecast period.
Parenteral peptide drugs are administered via routes that bypass the digestive systems, typically through injections such as intravenous (IV), intramuscular (IM), and subcutaneous (SC) administration. Parental peptide formulations are used to deliver peptides made up of amino acids and are easily degraded by the gastrointestinal tract enzymes if taken orally. The rising burden of diseases such as osteoporosis, cancer, cardiovascular diseases, and diabetes that fuel the demand for peptide therapeutics for managing the conditions is expected to boost segment growth. In addition, biotechnological advancement in peptide synthesis, drug design, and stability has improved the therapeutic potential of peptides. Advantages offered by the parenteral route of administration, and new product type approvals by key players are expected to drive segment growth over the forecast period.
The peptide therapeutics market segmentation includes marketing type, application, and route of administration. By marketing type, the market is segmented into generic and branded. By application, the market is segmented into gastrointestinal disorders, neurological disorders, metabolic disorders, cancer, and other applications. By route of administration, the market is segmented into parenteral, oral, and other routes of administration.
North America is Expected to Have a Major Share in the Market Over the Forecast Period
By geography, the North American region is likely to hold a major revenue share with an estimated market size of USD 18.29 billion in 2024, expected to reach USD 29.15 billion by 2029 with a CAGR of 9.77% over the forecast period. The North America peptide therapeutics market is expected to witness significant growth over the forecast period owing to factors such as the rising prevalence of chronic diseases, technological advancements in peptide drug delivery, and the increasing demand for targeted therapies among the population and new product launches by the key players in the market.
The rising number of people suffering from osteoporosis is expected to fuel the demand for peptide therapeutics. These drugs target specific pathways that regulate bone metabolism, offering more targeted and effective treatment options than traditional drugs. Some of the peptide therapeutics used for osteoarthritis are abaloparatide among others. According to a June 2023 article in Scientific Reports, the aging population in the United States is increasingly facing the public health challenge of osteoporotic fractures. Market trends and projections indicate that by 2025, the economic toll of these fractures will exceed USD 25 billion annually, with incidences surpassing 3 million each year. In addition, the data showed that about 12.6% of United States adults aged 50 and older have osteoporosis, while 43.1% have osteopenia, a condition that can lead to osteoporosis. Consequently, the significant prevalence of osteoporosis in the elderly heightens their susceptibility to bone fractures. This scenario is likely to drive the uptake of peptide therapeutics, notably teriparatide, which boosts bone density and mitigates the risk of both vertebral and non-vertebral fractures. As a result, this trend is projected to fuel market growth in the North America during the forecast period.
Moreover, the increased efforts by market participants to develop novel peptide therapeutic candidates for a range of indications are further expected to propel the region’s market growth over the study period. For instance, according to October 2024 data from the Clinical Trial. Gov, there were 3 active studies for peptide therapeutics in Mexico. The studies were mainly for indications like diabetes, neoplasms, and metabolic disorders. Therefore, such research efforts are further expected to bolster the region’s market growth over the study period.
By geography, the global market research is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). Asia-Pacific is expected to witness the highest growth rate. Global peptide therapeutics market analysis indicate that emerging markets like China and India are showing increasing demand due to expanding healthcare infrastructure, improving access to healthcare, and rising awareness about peptide-based treatments.

Peptide Therapeutics Industry Overview
The competitive landscape of the peptide therapeutics market is dynamic, with numerous players involved in the research, development, and commercialization of peptide-based therapies. Several global pharmaceutical and biotechnology companies are leading the way, while many smaller firms and startups are driving innovation, particularly in niche areas and novel drug delivery technologies.
Some of the key players currently dominating the market are Eli Lilly and Company, Amgen Inc., Pfizer Inc., Bristol Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd, AstraZeneca PLC, GlaxoSmithKline PLC, Novo Nordisk AS, Novartis AG, Zealand Pharma AG, SELLAS Life Sciences Group (Galena Biopharmaceuticals). In addition, companies focus on launching new products along with approvals in various countries which is likely to increase the availability of the products in the market.
For instance, in November 2023, Eli Lilly and Company received approval from the United States Food and Drug Administration (FDA) for its Zepbound (tirzepatide) injection. Zepbound is intended for adults with obesity (BMI of 30 kg/m2 or higher) or those who are overweight (BMI of 27 kg/m2 or more) and have weight-related medical conditions such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease. In addition, advances in drug delivery systems, biosimilars, and personalized medicine are key trends that will shape the competitive dynamics in the coming years.
Peptide Therapeutics Market Leaders
-
Eli Lilly and Company
-
Amgen Inc.
-
Bristol-Myers Squibb Company
-
GlaxoSmithKline PLC
-
AstraZeneca PLC
- *Disclaimer: Major Players sorted in no particular order

Peptide Therapeutics Market News
- August 2024: Eli Lilly and Company made Zepbound (tirzepatide) available in 2.5 mg and 5 mg single-dose vials for self-pay patients holding on-label prescriptions.
- July 2024: Pfizer Inc. revealed its preferred once-daily modified-release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist, following results from the ongoing pharmacokinetic study.
- July 2024: AstraZeneca acquired of Amolyt Pharma, a clinical-stage biotech firm dedicated to pioneering treatments for rare endocrine disorders. This acquisition enhances the late-stage pipeline of Alexion, a part of AstraZeneca Rare Disease, and strengthens its bone metabolism portfolio.
- June 2024: Teva Pharmaceuticals launched a generic version of Victoza, initially developed by Novo Nordisk A/S, for treating type 2 diabetes. This introduction marks the first generic GLP-1 drug in the United States, a market experiencing significant demand. Initially approved for diabetes treatment, GLP-1 drugs are also prescribed for obesity.
Peptide Therapeutics Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Prevalence of Cancer and Metabolic Disorders
- 4.2.2 Rising Investments in Research and Development of Novel Drugs
- 4.2.3 Technological Advancements
-
4.3 Market Restraints
- 4.3.1 Instability of Peptides
- 4.3.2 High Cost of Developing Drugs and Stringent Regulatory Requirements for Drug Approval
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value in USD billion)
-
5.1 By Marketing Type
- 5.1.1 Generic
- 5.1.2 Branded
-
5.2 By Application
- 5.2.1 Gastrointestinal Disorders
- 5.2.2 Neurological Disorders
- 5.2.3 Metabolic Disorders
- 5.2.4 Cancer
- 5.2.5 Other Applications
-
5.3 By Route of Administration
- 5.3.1 Parenteral
- 5.3.2 Oral
- 5.3.3 Other Routes of Administration
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Eli Lilly and Company
- 6.1.2 Amgen Inc.
- 6.1.3 Pfizer Inc.
- 6.1.4 Bristol-Myers Squibb Company
- 6.1.5 Ever Neuro Pharma GmbH
- 6.1.6 Takeda Pharmaceutical Company Limited
- 6.1.7 Teva Pharmaceuticals Industries Ltd
- 6.1.8 AstraZeneca PLC
- 6.1.9 GlaxoSmithKline PLC
- 6.1.10 Novo Nordisk AS
- 6.1.11 Novartis AG
- 6.1.12 Zealand Pharma AG
- 6.1.13 SELLAS Life Sciences Group (Galena Biopharmaceuticals)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Peptide Therapeutics Industry Segmentation
As per the report's scope, Peptides are short chains of amino acid monomers linked by peptide bonds. Peptides are distinguished from proteins based on size and, as a benchmark, can be understood to contain approximately 50 amino acids or less.
The peptide therapeutics market segmentation includes marketing type, application, route of administration, and geography. By marketing type, the market is segmented into generic, and branded. By application, the market is segmented into gastrointestinal disorders, neurological disorders, metabolic disorders, cancer, and other applications. By route of administration, the market is segmented into parenteral, oral, and other routes of administration. By geography, the global market is segmented into North America (United States, Canada, Mexico), Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific), Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa), and South America (Brazil, Argentina, Rest of South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the market value (in USD billion) for the above segments. By Marketing Type Generic Branded By Application Gastrointestinal Disorders Neurological Disorders Metabolic Disorders Cancer Other Applications By Route of Administration Parenteral Oral Other Route of Administration By Geography North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific China Japan India Australia South Korea Rest of Asia Pacific Middle East and Africa GCC South Africa Rest of Middle East and Africa South America Brazil Argentina Rest of South America
By Marketing Type | Generic | ||
Branded | |||
By Application | Gastrointestinal Disorders | ||
Neurological Disorders | |||
Metabolic Disorders | |||
Cancer | |||
Other Applications | |||
By Route of Administration | Parenteral | ||
Oral | |||
Other Routes of Administration | |||
Geography | North America | United States | |
Canada | |||
Mexico | |||
Europe | Germany | ||
United Kingdom | |||
France | |||
Italy | |||
Spain | |||
Rest of Europe | |||
Asia-Pacific | China | ||
Japan | |||
India | |||
Australia | |||
South Korea | |||
Rest of Asia-Pacific | |||
Middle East and Africa | GCC | ||
South Africa | |||
Rest of Middle East and Africa | |||
South America | Brazil | ||
Argentina | |||
Rest of South America |
Peptide Therapeutics Market Research FAQs
How big is the peptide industry?
The peptide therapeutics market size is expected to reach USD 43.36 billion in 2025 and grow at a CAGR of 7.06% to reach USD 65.20 billion by 2030.
What are the challenges of peptide therapeutics?
The key challenges hindering the growth of the peptide therapeutics market are high production costs, complex manufacturing processes, and limited commercialization of peptide drugs.
What is the future of peptide therapeutics?
The future of peptide therapeutics looks promising, with advancements in drug design, targeted delivery systems, and personalized medicine poised to enhance their efficacy and expand their applications in treating a wide range of diseases.
What is the market outlook for peptides?
The market for peptides is expected to experience significant growth, driven by increasing demand for peptide-based drugs, advancements in peptide synthesis technologies, and expanding applications in oncology, metabolic disorders, and autoimmune diseases.
What are the disadvantages of peptide therapeutics?
Peptide therapeutics face challenges such as poor oral bioavailability, susceptibility to enzymatic degradation, and high production costs.